Basics Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. IPO Date: April 14, 2004 Sector: Healthcare Industry: Pharma Market Cap: $7.55B Activated in VL: True Average Daily Range Avg Daily Range: $0.27 | 2.79% Avg Daily Range (30 D): $1.16 | 1.57% Avg Daily Range (90 D): $2.06 | 2.79% Institutional Daily Volume Avg Daily Volume: .47M Avg Daily Volume (30 D): 1.11M Avg Daily Volume (90 D): 1.28M Trade Size Avg Trade Size (Sh.): 104 Avg Trade Size (Sh.) (30 D): 45 Avg Trade Size (Sh.) (90 D): 48 Institutional Trades Total Inst.Trades: 4,165 Avg Inst. Trade: $2.51M Avg Inst. Trade (30 D): $5.22M Avg Inst. Trade (90 D): $4.81M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.45M Avg Closing Trade (30 D): $11.21M Avg Closing Trade (90 D): $12.85M Avg Closing Volume: 138.24K     News May 8, 2025 @ 5:00 PM High- and Low-Grade Serous Ovarian Cancer Market i... Source: Delveinsight Dec 11, 2024 @ 6:00 PM Alcohol Use Disorder Market Set for Remarkable Gro... Source: Delveinsight Sep 19, 2024 @ 7:36 PM Corcept Moves 6.5% Higher: Will This Strength Last... Source: Zacks Sep 3, 2024 @ 8:29 PM Corcept Shares Rise More Than 45% in Six Months: H... Source: Zacks Aug 6, 2024 @ 10:20 AM Should You Invest in the First Trust NYSE Arca Bio... Source: Zacks Investment Research Financials   TTM Q1 2025 Q4 2024 Basic EPS $1.27 $.19 $.29 Diluted EPS $1.15 $.17 $.25 Revenue $ 685.45M $ 157.21M $ 181.89M Gross Profit $ 674.7M $ 154.81M $ 178.93M Net Income / Loss $ 133.99M $ 20.55M $ 30.75M Operating Income / Loss $ 110.87M $ 3.42M $ 25.26M Cost of Revenue $ 10.75M $ 2.4M $ 2.96M Net Cash Flow $ -59.93M $ -37.85M $ -9.62M PE Ratio 0.00